Literature DB >> 7875239

Effects of activin A/erythroid differentiation factor on erythroid and megakaryocytic differentiations of mouse erythroleukemia (Friend) cells: evidence for two distinct modes of cell response.

K Okafuji1, K Kaku, M Seguchi, H Tanaka, Y Azuno, T Kaneko.   

Abstract

To further characterize activin A/erythroid differentiation factor (EDF) action on hematopoietic cell differentiation, we examined the effects of activin A/EDF on megakaryocytic and erythroid differentiation by determining acetylcholinesterase (AchE) activity and hemoglobin production in the mouse erythroleukemia (MEL) cell line F55. Activin A/EDF induced AchE activity of F55 cells in a dose-dependent manner. Erythroid differentiation of F55 cells, which was characterized by an increase in dianisidine-positive cells, was also induced by activin A/EDF. The effect of activin A/EDF on hemoglobin synthesis appeared more slowly compared with the effect on AchE activity. Erythroid differentiation induced by activin A/EDF was affected by the initial cell density, but AchE activity was not. Sodium orthovanadate, a tyrosine phosphatase inhibitor, markedly inhibited activin A/EDF-induced erythroid differentiation but not activin A/EDF-induced AchE activity. Other erythroid differentiation inducers, sodium butyrate and butyrylcholine chloride, mildly increased AchE activity in F55 cells, but N,N'-hexamethylene-bis-acetamide (HMBA), dimethyl sulfoxide (DMSO), and genistein did not. Dexamethasone inhibited HMBA-induced erythroid differentiation but did not affect activin A/EDF or sodium butyrate action. These results suggest that F55 cells potentially can differentiate into cells of a megakaryocytic lineage in addition to an erythroid lineage, and that activin A/EDF further potentiates the cell differentiation of this cell line. In addition, our results suggest that the mode of activin A/EDF effects on megakaryocytic differentiation is distinct from that on erythroid differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875239

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

1.  Interleukin-1 beta enhances and interferon-gamma suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts.

Authors:  M Abe; Y Shintani; Y Eto; K Harada; Y Fujinaka; M Kosaka; T Matsumoto
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

2.  Activin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures.

Authors:  Tristan W Fowler; Archana Kamalakar; Nisreen S Akel; Richard C Kurten; Larry J Suva; Dana Gaddy
Journal:  J Cell Sci       Date:  2015-01-20       Impact factor: 5.285

Review 3.  Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.

Authors:  Kristy M Nicks; Daniel S Perrien; Nisreen S Akel; Larry J Suva; Dana Gaddy
Journal:  Mol Cell Endocrinol       Date:  2009-07-15       Impact factor: 4.102

4.  Phytoestrogens genistein and daidzin enhance the acetylcholinesterase activity of the rat pheochromocytoma cell line PC12 by binding to the estrogen receptor.

Authors:  Hiroko Isoda; Terence P N Talorete; Momoko Kimura; Takaaki Maekawa; Yuhei Inamori; Nobuyoshi Nakajima; Humitake Seki
Journal:  Cytotechnology       Date:  2002-11       Impact factor: 2.058

Review 5.  Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.

Authors:  Toshifumi Sugatani
Journal:  Int J Mol Sci       Date:  2018-08-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.